Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.
RWE in Older Patients with Acute Myeloid Malignancies
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world evidence (RWE) in older patients with acute myeloid malignancies.
Role of Venetoclax in Treatment of MDS @YaleCancer
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer
elaborates on the role of venetoclax in treatment of myelodysplastic syndromes (MDS).
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, shares outcomes from the PRIMO study investigating duvelisib in peripheral T-cell lymphoma (PTCL).
Novel Approaches in Development for the Treatment of PTCL
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, tells us about some of the novel approaches in development for the treatment of peripheral T-cell lymphoma (PTCL).
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, discusses the most impressive studies in the treatment of peripheral T-cell lymphoma (PTCL) presented at ASH 2019.
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years.
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma.
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL).
1st Line Brentuximab Vedotin + Nivolumab @TheUSONetwork
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma.
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.
Clinical Data That Lead to the FDA Approval of Zanubrutinib @MDAndersonNews
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead to the FDA approval of zanubrutinib.
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.